A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Solid Cancers.
Phase of Trial: Phase I
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Paclitaxel (Primary) ; Sirolimus
- Indications Solid tumours
- Focus Adverse reactions
- 13 Jan 2014 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 16 Jun 2009 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 05 Oct 2006 New trial record.